These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25338994)

  • 1. HER2 expression in ovarian mucinous carcinomas in Tunisia.
    Missaoui N; Abdelkarim SB; Ayachi M; Hmissa S; Yaacoubi MT
    Asian Pac J Cancer Prev; 2014; 15(19):8121-5. PubMed ID: 25338994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
    Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
    Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
    Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
    Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
    Ye F; Hu Y; Zhou C; Hu Y; Chen H
    Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
    Yousif HMA; Mohammed RAA
    Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
    Kim SK; Cho NH
    Int J Clin Exp Pathol; 2014; 7(7):4222-30. PubMed ID: 25120802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
    Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
    Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
    McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
    BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
    Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
    Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
    Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
    Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Matuura H; Miyamoto M; Takano M; Soyama H; Aoyama T; Yoshikawa T; Kato K; Sakamoto T; Kuwahara M; Takasaki K; Ishibashi H; Iwahashi H; Tsuda H; Furuya K
    Anticancer Res; 2018 Feb; 38(2):717-722. PubMed ID: 29374695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
    Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
    Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?
    Demir L; Yigit S; Sadullahoglu C; Akyol M; Cokmert S; Kucukzeybek Y; Alacacioglu A; Cakalagaoglu F; Tarhan MO
    Asian Pac J Cancer Prev; 2014; 15(22):9739-45. PubMed ID: 25520097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
    Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
    Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer.
    Sueblinvong T; Manchana T; Khemapech N; Triratanachat S; Termrungruanglert W; Tresukosol D
    Asian Pac J Cancer Prev; 2007; 8(4):502-6. PubMed ID: 18260719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin in ovary tumors.
    Plewka D; Jakubiec-Bartnik B; Morek M; Bogunia E; Bienioszek M; Wolski H; Kotrych D; Dziekan K; Seremak-Mrozikiewicz A; Plewka A
    Ginekol Pol; 2015 Jul; 86(7):525-30. PubMed ID: 26376531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.